The discovery of three previously unknown kinases that are essential for signaling in response to tumour necrosis factor and interleukin-1 has provided the missing link in the pathway that activates inflammatory genes.
Inflammation disorders, such as rheumatoid arthritis, asthma and inflammatory bowel disease, can be considered as 'gene expression diseases' in which the proinflammatory gene program of the organism is aberrantly activated. The complexity of the inflammatory phenotype can be attributed to the induction of the expression of a vast number of proteins with distinct activities, which together cause the various molecular and cellular events that distinguish normal tissue from inflamed tissue.
A hallmark of many genes that are switched on in inflammatory diseases is that their expression can be induced by the cytokines tumor necrosis factor (TNF) and interleukin-1 (IL-1). Increased levels of these two cytokines have been linked to numerous inflammatory diseases; in addition, TNF-neutralizing antibodies have been efficacious in the treatment of rheumatoid arthritis and inflammatory bowel disease [1] . Upon binding to their cell-surface receptors, both TNF and IL-1 activate a cytoplasmic form of the transcription factor NF-κB [2, 3] . DNA-binding motifs for NF-κB are found in the promoters and enhancers of more than 50 genes that are known to be activated upon inflammation [4] , and in most cases the induction of these genes has been shown to rely on the binding of activated NF-κB to their regulatory sequences.
One of the physiological roles of NF-κB is to induce the expression of defense genes rapidly upon life-threatening conditions, such as viral and bacterial infections or physical stress. This transcription factor is particularly suited for such a function because it is found in almost every type of cell in a 'pre-made' form in the cytoplasm, where it is held in an inactive protein complex with its inhibitor, IκB. In chronically inflamed tissue, in which external pathogenic stimuli seem to be absent, TNF and IL-1 act as the primary endogenous inducers of NF-κB. When cells are exposed to TNF or IL-1, a cascade of events leads to the phosphorylation and subsequent degradation of IκB with the result that NF-κB is then liberated to enter the nucleus and activate gene expression [2, 3] .
Although the basic principle of NF-κB regulation was understood several years ago [5] , it was more difficult to elucidate the mechanism of activation of NF-κB in the cytoplasm upon triggering the cell-surface receptors for TNF and IL-1. More detailed studies revealed that the IκB inhibitor is removed from NF-κB by conjugation of IκB to ubiquitin and its subsequent proteasome-dependent proteolysis. This two-step process is triggered by the phosphorylation of two serine residues in the amino-terminal portion of IκB proteins. Many earlier studies proposed the involvement of known kinases, but none of these kinases could match the requirements for an IκB kinase. In a 1996 study, biochemical characterization revealed that the actual IκB kinase is apparently contained within a large 600-700 kDa complex [6] , but the study gave no clue as to its identity.
Other labs have tried to unravel the pathway leading to NF-κB activation by starting from the TNF and IL-1 receptors at the cell surface. Using the intracellular domains of these receptors in biochemical purification studies and yeast two-hybrid cloning analysis, recent years have led to the discovery of several novel proteins, including protein kinases, that are recruited to the cytoplasmic portion of the receptors and thereby relay the activation signal towards IκB ( [7] [8] [9] [10] and see below). Only the past few months may have seen the conclusion of this puzzle, with the discovery of previously unknown protein kinases that eventually allow us to follow the complete TNF/IL-1 signaling pathway from the cell surface into the cell nucleus. In this dispatch, the initial separate stages and the common steps of the TNF and IL-1 signaling pathways as they appear after the recent seminal discoveries ( Figure 1 ) will be discussed.
The TNF receptor (TNFR) subtype that plays a predominant role in the pro-inflammatory actions of TNF is TNFR1 [7] . Binding of the trimeric TNF ligand to the extracellular domain of TNFR1 induces aggregation of the death domains (DDs) -protein-protein interaction motifs -within the cytoplasmic portion of the receptor. The oligomerized DDs of the receptor act as a scaffold for the assembly of a signaling complex containing at least three different protein components: the TNFR-associated death-domain protein, TRADD; the TNFR-associated factor 2, TRAF2; and receptor-interacting protein, RIP [11] [12] [13] . TRADD itself has a DD through which it multimerizes and associates with the DDs of the TNFR, acting as an adaptor molecule to recruit the other two components, TRAF2 and RIP. TRAF2 associates with the amino-terminal half of TRADD, whereas RIP interacts through its own DD with the DD of TRADD. TRAF2 and RIP also interact with each another, possibly stabilizing the complex. Of the three proteins in this signaling complex, only RIP has a known intrinsic enzymatic activity as it contains an amino-terminal serine/threonine-specific kinase domain. Although RIP is essential for NF-κB induction by TNF, its kinase activity does not appear to be required for this function [14] . More experimental evidence is required, however, to conclusively rule out a direct involvement of the RIP kinase domain.
TRAF2 is a member of a new family of signaling proteins that is characterized by the presence of a conserved TRAF domain of approximately 230 amino acids in the carboxyterminal portion, and multiple zinc-finger motifs within the amino-terminal half. The TRAF domain mediates homotypic and heterotypic interactions and is also involved in binding to other signaling molecules and members of the TNFR superfamily. Six TRAF proteins have been identified to date that are involved in signaling by various TNFR superfamily members.
Although the IL-1 receptor (IL-1R) is entirely unrelated in sequence to members of the TNFR superfamily, NF-κB activation by IL-1 also involves a TRAF protein. Activation of the IL-1R by IL-1 induces receptor aggregation and full activation requires an accessory membrane-spanning protein, AcP. Like the TNFR, the activated IL-1R-AcP complex recruits a cytoplasmic complex of a serine/threonine kinase and a TRAF protein -IL-1R-activated kinase (IRAK) [15] and TRAF6 [16] , respectively. This raises the issue of how the unrelated receptors use their specific signaling complexes -TRADD-RIP-TRAF2 for TNFR1, and IRAK-TRAF6 for the IL-1R-AcP receptor complex -to trigger phosphorylation of IκB on the same serine residues, when the kinases RIP and IRAK are unrelated and clearly do not phosphorylate IκB directly.
The first signaling protein common to TNF and IL-1 pathways emerged as a novel mitogen-activated protein kinase kinase kinase (MAPKKK) called NF-κB-inducing kinase (NIK), which was identified in a yeast two-hybrid screen for TRAF2-interacting proteins [17] . NIK, which can also interact with TRAF6 [18] , activates NF-κB when overexpressed, and a kinase-inactive NIK mutant protein blocks NF-κB activation mediated both by TNF and IL-1 treatment and TRAF2 and TRAF6 overexpression. These and other observations place NIK downstream of the TRAFs and at a point at which the TNF and IL-1 signaling pathways converge.
The link between NIK, which alone cannot phosphorylate IκB, and the signal-induced phosphorylation of IκB has been established by the discovery of a NIK-interacting protein kinase, termed IκB kinase α (IKK-α), in a yeast two-hybrid screen using NIK as bait [19] . The same protein was discovered as a component of a purified IKK complex [20, 21] . The kinase, which has a conserved helix-loop-helix motif, had been cloned in previous studies but its function remained unknown [22] . IKK-α can phosphorylate various IκB proteins at the critical serine residues and apparently acts in a complex with NIK to phosphorylate NF-κB-bound IκB, thus triggering the degradation of the inhibitor.
An expressed sequence tag (EST) database search [20] and protein purification studies [21, 23] revealed the existence of a second IκB kinase, termed IKK-β, which shares more than 50% identity with IKK-α [24] . Overexpression of both IKKs activates NF-κB and kinase-inactive forms 
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Cytoplasm function as transdominant negative mutants. Consistent with a role for these kinases in cytokine signaling, IKK activities are stimulated upon treatment of cells with TNF. IKK-α and IKK-β can each form homodimers but seem to prefer to form heterodimers. The IKK-αβ heterodimer binds tightly to NIK, forming an unusual signaling complex composed of three distinct kinases. A major focus of research now will be to understand how NIK is activated in response to the assembly of upstream signaling proteins on the receptors and how the signal is relayed through a complex of three distinct kinases. With the identification of the IKKs and NIK, a contiguous pathway linking TNF and IL-1 signaling pathways from the cell surface to the cytoplasmic NF-κB-IκB complex has finally been outlined. The beauty of these pathways lies in the fact that the components were shown to interact physically with their respective upstream or downstream partners, providing the experimental basis for its revelation.
An obvious question is whether we now know all of the essential components required for activation of NF-κB in response to TNF (and IL-1). In support of this idea is the fact that all presently known protein components can physically interact with each other in turn: TNF-TNFR1-TRADD-RIP-TRAF2 with NIK-IKKs with IκB-NF-κB. Each of these protein-protein interactions was sufficently strong to allow the identification of the subsequent component by either biochemical purification or using two-hybrid screening in yeast. Perhaps there are more signaling components to be discovered that associate peripherally with the known components and, for example, allow branching into other signaling pathways.
Another component yet to be discovered is an E3 ligase that specifically recognizes doubly phosphorylated IκB and initiates its conjugation to ubiquitin and its subsequent degradation [25] .
The TNF signaling pathway is less similar to a diffusioncontrolled enzymatic cascade and more like a linear signalrelay system that extensively exploits tight physical interactions of enzymatic and non-enzymatic components. Why has this signal transduction pathway apparently evolved away from a catalytic cascade towards a more stoichiometric method of signal transfer? The TNF and IL-1 signaling pathways are a prime target for every kind of invading bacterium or virus, as inhibition of NF-κB activation will potently immunocompromise the host. Whereas viruses use their own proteins to overwhelm the cellular defense systems, bacteria and other micro-organisms frequently use low molecular-weight metabolites, such as cyclosporin or rapamycin, to suppress the immune response. If the NF-κB signaling system could be successfully blocked by such a small molecule during an infection, the affected organism would no longer survive. The system must therefore be subject to immense selective pressure to escape inhibition by small molecules. (3) The pathway uses essential cellular enzymes that have an important role in cell survival: if these enzymes are hit by a small molecule, the cell will die before it can propagate the intruder. The use of essential enzymes may be the reason why IκB inactivation relies on the ubiquitin-proteasome system, which also has an important role in the regulation of cell-cycle progression. In this context, it will be very interesting to study the phenotypes of IKK and NIK null mutants. (4) NF-κB is involved in an anti-apoptotic genomic response. As reviewed recently [26] , some cell types will die in response to TNF if NF-κB activation is blocked. (5) Tight enzymatic complexes are formed that may not be easily accessible to small molecules: this could explain why the IKKs are contained in a large complex of 700 kDa together with the NF-κB-IκB substrate and presumably NIK. (6) Enzymatic activities are redundant: the two IKKs seem to be functionally redundant and may require distinct inhibitory molecules to be inactivated.
The newly discovered kinases in the TNF/IL-1 signaling pathway -IKK-α, IKK-β and NIK -would be attractive targets for the development of novel anti-inflammatory drugs. Similarly, these kinases are interesting signaling molecules for further study because of their ability to form a trimer and also because the mechanism of stimulating the kinase activity of NIK by apparently non-enzymatic signaling proteins is as yet unknown. An intriguing possibility is that transient contact with upstream regulators might lead to a prolonged alteration of the activity state of the NIK-IKK-α-IKK-β kinase trimer. Such 'molecular memory' based on (auto)phosphorylation has been observed in another system, in which it promotes the long-lasting calcium-independent activation of calcium/calmodulin-dependent protein kinase II, a major component of the postsynaptic density in neurons [27] .
